Heart Disease and Erectile Dysfunction

ISBN-13: 9781588292162 / Angielski / Twarda / 2004 / 300 str.

Robert A. Kloner; Robert A. Kloner; Robert A. Kloner

Opis

Senior physicians, cardiologists, urologists, psychologists, and pharmacologists critically review the relation between heart disease and erectile dysfunction (ED) and explain for the practicing physician the effective new treatment options available for the cardiac patient with ED. The authors detail in concise language the latest thinking about the risk of sexually induced cardiac events, the efficacy and risks to cardiac patients of drugs used to treat sexual dysfunction, and the expert guidelines developed by prominent organizations on the optimal approach to sexual dysfunction in the cardiac patient. They also discuss the physiology of ED and the currently available therapies (sildenafil, tadalafil, and vardenafil) may interact with the cardiac system, and the potential application of newer agents like phosphodiesterase-5 inhibitors to cardiovascular disease.

Recenzje

"This is the first book of its kind. Dr. Cloner and colleagues deserve credit for bringing this important topic to the forefront." - Doody's Health Sciences Book Review Journal

Spis treści

Physiology of Erection and Causes of Erectile Dysfunction Aristotelis G. Anastasiadis, Dmitry Droggin, Martin Burchardt, and Ridwan Shabsigh Erectile Dysfunction: The Scope of the Problem Culley C. Carson Erectile Dysfunction and Cardiovascular Risk Factors Robert A. Kloner Psychologic Aspects of Erectile Dysfunction in Heart Patients Raymond C. Rosen Management of Erectile Dysfunction: An Overview Harin Padma-Nathan Sildenafil Citrate and the Nitric Oxide/Cyclic Guanosine Monophosphate Signaling Pathway Ian H. Osterloh and Stephen C. Phillips Phosphodiesterase-5 Inhibition: Importance to the Cardiovascular System Jackie D. Corbin, Stephen R. Rannels, and Sharron H. Francis The Hemodynamics of Phosphodiesterase-PDE5 Inhibitors Graham Jackson Cardiovascular Safety of Phosphodiesterase-5 Inhibitors Robert A. Kloner Effect of Phosphodiesterase-5 Inhibition on Coronary Blood Flow in Experimental Animals YingJie Chen, Jay H. Traverse, and Robert J. Bache Safety and Hemodynamic Effects of Sildenafil in Patients With Coronary Artery Disease Sameer Rohatgi and Howard C. Herrmann Cardiovascular Effects of Nonphosphodiesterase-5 Inhibitor Erectile Dysfunction Therapies Harin Padma-Nathan Potential Cardiac Applications of Phosphodiesterase Type-5 Inhibition Michael Sweeney and Richard L. Siegel The Physiologic Cost of Sexual Activity Robert F. DeBusk Sexual Activity As a Trigger of Myocardial Infarction/Ischemia: Implications for Treating Erectile Dysfunction Robert A. Kloner Sex After Cardiac Events and Procedures: Counseling From the Cardiovascular Specialist's Perspective Herman A. Taylor, Jr. American College of Cardiology/American Heart Association Guidelines on the Use of Sildenafil in Patients With Cardiovascular Disease Adolph M. Hutter, Jr. Risk of Heart Attack After Sexual Activity: The Princeton Guidelines and Their Rationale Robert F. DeBusk Index

Blurb

It is now generally appreciated that heart disease and its attendant risk factors are a leading cause of erectile dysfunction (ED) and that ED is often an early warning sign of vascular disease. In Heart Disease and Erectile Dysfunction, senior physicians, cardiologists, urologists, psychologists, and pharmacologists critically review the relationship between heart disease and erectile dysfunction and explain for the practicing physician the effective new treatment options available for the cardiac patient with ED. The authors detail in concise language the latest thinking about the risk of sexually induced cardiac events, the efficacy and risks to cardiac patients of drugs used to treat sexual dysfunction, and the expert guidelines developed by prominent organizations on the optimal approach to sexual dysfunction in the cardiac patient. They also discuss the physiology of ED and how the currently available therapies (sildenafil, tadalafil, and vardenafil) may interact with the cardiac system, and the potential application of newer phosphodiesterase-5 inhibitors to cardiovascular disease.
Comprehensive and pathbreaking, Heart Disease and Erectile Dysfunction not only clearly delineates for practicing physicians all aspects of the interaction between the vascular system and erectile dysfunction, but also establishes a sound medical basis for the management of cardiac patients suffering erectile disorders.